Drugs battles prove a headache for patent owners
Shahnaz Mahmud, New York and James Nurton, London
The world's two biggest-selling drugs are at the centre of patent disputes that demonstrate the increasingly aggressive stance generic companies are taking against blockbuster drugs coming towards the end of their patent life.
Drugs company Pfizer stands to lose more...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.